Analginum таб. 500 mg, No. 10 Comte./cell.

General characteristics. Structure:

Active agent: metamizole sodium - 500 mg excipients: refined sugar (sucrose), potato starch, calcium stearate 1-water, talc.

Pharmacological properties:

Possesses anesthetic, febrifugal and weak antiinflammatory action, is derivative pyrazyl ketone.

Pharmacodynamics. Analginum not selectively blocks cyclooxygenase and reduces formation of prostaglandins from arachidonic acid, interferes with carrying out painful extra-and proprioceptive impulses. Analginum has poorly expressed antiinflammatory effect causing small influence on a water salt metabolism (a delay of sodium and water) and mucous a GIT. Has spasmolytic effect on smooth muscles of uric and bilious ways. Action develops in 20-40 minutes after intake.

Pharmacokinetics. It is well and quickly soaked up from a GIT that provides bystry development of clinical effect. At reception in therapeutic doses gets into maternal milk. The maximum concentration in plasma is reached in 1-1,5 h after intake. In a wall of intestines it is hydrolyzed with formation of an active metabolite, 4-methyl-amino-antipyrine which is in turn metabolized in 4-formyl-amino-antipyrine and other metabolites. Level of linkng of an active metabolite with proteins makes 50-60%. Excretion of metabolites passes through kidneys. Besides, metabolites are allocated with breast milk.

Indications to use:

Feverish syndrome against the background of infectious and inflammatory diseases, a headache of various genesis, a pain syndrome of weak and moderate expressiveness: neuralgia, mialgiya, arthralgia, bilious colic, intestinal colic, renal colic, injuries, radiculitis, miositis, postoperative pain syndrome, альгодисменорея.

Route of administration and doses:

Inside, after food, the adult appoint 250-500 mg 2-3 times a day, the maximum single dose – 1000 mg, daily – 3000 mg. Single doses for children of 8-14 years – 250-300 mg, frequency rate of appointment 2-3 times a day. Reception duration without consultation with the doctor no more than 5 days.

Features of use:

At treatment of children up to 8 years and the patients receiving cytostatic medicines, reception of Analginum has to be carried out only under observation of the doctor. Patients with atopic bronchial asthma and pollinoses have an increased risk of development of allergic reactions. Against the background of reception of Analginum development of an agranulocytosis in this connection, at identification of unmotivated rise in temperature, a fever, pharyngalgias, the complicated swallowing, stomatitis, and also at development of the phenomena of a vaginitis or proctitis immediate drug withdrawal is necessary is possible. At prolonged use it is necessary to control a pattern of peripheral blood. Use for removal of acute abdominal pains is inadmissible (before clarification of the reason).

Side effects:

From an urinary system: a renal failure, an oliguria, an anury, a proteinuria, intersticial nephrite, coloring of urine in red color.

Allergic reactions: a small tortoiseshell (including on a conjunctiva and mucous membranes of a nasopharynx), a Quincke's disease, in rare instances – a malignant exudative erythema (Stephens-Johnson's syndrome), a toxic epidermal necrolysis (Lyell's disease), a bronkhospastichesky syndrome, an acute anaphylaxis.

From bodies of a hemopoiesis: agranulocytosis, leukopenia, thrombocytopenia. Other: lowering of arterial pressure.

Interaction with other medicines:

Co-administration with other non-narcotic analgesics, tricyclic antidepressants, contraceptive hormonal medicines and Allopyrinolum can lead to toxicity strengthening; sedative and anxiolytic medicines strengthen analgeziruyushchy effect of metamizole sodium. Metamizole sodium strengthens effects of alcohol; simultaneous use with Chlorpromazinum or fenotiaziny can lead to development of the expressed hyperthermia. X-ray contrast medicines, colloid blood substitutes and penicillin should not be applied during treatment by metamizole sodium. At co-administration of cyclosporine concentration of the last in blood decreases. Metamizole sodium, forcing out peroral hypoglycemic drugs, indirect anticoagulants, corticosteroids and indometacin from communication with protein, increases their activity. Phenylbutazone, barbiturates and other inductors of a microsomal oxidation of a liver at co-administration reduce efficiency of metamizole sodium.

Contraindications:

Hypersensitivity, hemopoiesis oppression (agranulocytosis, neutropenia), liver and/or renal failure, the hereditary hemolitic anemia connected with deficit glyukozo-6-fosfatdegidrogenazy and other types of anemia, "aspirinovy" asthma, a leukopenia, pregnancy (especially in the I trimester and in the last 6 weeks), the lactation period, children's age up to 8 years.

Overdose:

Symptoms: nausea, vomiting, gastralgia, oliguria, hypothermia, lowering of arterial pressure, tachycardia, short wind, sonitus, drowsiness, nonsense, consciousness disturbance, acute agranulocytosis, hemorrhagic syndrome, acute renal and/or liver failure, spasms, paralysis of respiratory muscles. Treatment: a gastric lavage, salt laxatives, absorbent carbon, carrying out an artificial diuresis, a hemodialysis, at development of a convulsive syndrome – intravenous administration of diazepam and high-speed barbiturates.

Storage conditions:

List B. In dry, protected from light and the place, unavailable to children, at a temperature not above +25 °C.

Issue conditions:

Without recipe

Packaging:

Tablets on 500 mg. On 10 tablets in planimetric strip or bezjyacheykovy packaging. 2 or 3 blister strip packagings together with the application instruction place in a pack from a cardboard. It is allowed to stack planimetric strip or bezjyacheykovy packagings with the equal number of application instructions in a box from a cardboard bandbox.